AACR 2023 | Phase II trial of nivolumab with SOC in the management of GG5 prostate cancer

John Michael Bryant, MD, Moffitt Cancer Center, Tampa, FL, shares the interim-analysis of a Phase II trial (NCT03543189) assessing the combination of nivolumab with standard of care (SOC) in the management of grade group 5 (GG5) prostate cancer. Patients were required to have GG5 prostate cancer with more than 30% positive cores and receive nivolumab plus SOC regimen, comprising androgen deprivation therapy (ADT), external beam RT (EBRT), and high dose rate brachytherapy (HDR). The combination of nivolumab with SOC for GG5 prostate cancer is safe and associated with a clinically significant improvement in disease control. Ricketts_Immunosuppression was identified as a potential biomarker for immune checkpoint inhibitor (ICI)-sensitive tumor subtypes. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.